Skip to main content
RXRX logo

RXRX · Recursion Pharmaceuticals, Inc.

Track RXRX — free
$2.50 -0.22 (-8.09%)
Market Cap
$1.53B
Shares
622.76M
Volume · Nov 20 29.66M Avg daily vol (3M) 24.44M

Price & Indicators

 

Key stats

Close
$2.45
Fri 20 Nov
Open
$2.63
Fri 20 Nov
Average volume, 30 days
25.6M
shares a session
Short interest
142.3M
22.8% of shares · 6.1 days to cover
Day range
$2.44$2.76
Open $2.63 Close $2.45
52-week closing range
$2.45$4.96
Close $2.45 50.6% under the high
Short volume, last session
57%
Last earnings
Nov 3, 2026
Latest filing
10-Q · Nov 2
Price history
Apr 2021 to Nov 2026

Up next

Feb 24, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 2
Quarterly report 10-Q FY2026 Q3, ended Sep 30
87% of FAP patients see polyp burden fall on REC-4881

Recursion reported further positive data from its Phase 1b/2 TUPELO trial of REC-4881 in FAP. After 12 weeks, 87% of patients (13 of 15) had reduced total polyp burden, with a 47% median reduction.

Revenue $18.55M ▲ 258.5% Net loss $119.04M Diluted EPS -$0.22
Read from the MD&A section
2 source passages
On November 2, Recursion announced further positive data from its ongoing Phase 1b/2 TUPELO trial of REC-4881, an investigational, oral MEK1/2 inhibitor in development for FAP. After 12 weeks of REC-4881 (4 mg QD), 87% of patients (13 of 15) had a reduction in total polyp burden, with a 47% median reduction Open the document at this passage
Nov 2
Current report 8-K Events of Oct 31
REC-4881 Phase 2 Data Show 47% Median Polyp Burden Reduction

Recursion presented Phase 2 REC-4881 data showing a 47% median polyp burden reduction in FAP patients after 12 weeks. Also, 85% of evaluable patients remained below baseline 12 weeks off treatment.

Financial results, Director or officer change, or executive pay, Regulation FD disclosure Read from the first part of this long document
3 source passages
New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP In an expanded adult population aged 18 years and older, after 12 weeks of treatment, patients achieved a 47% median reduction in total polyp burden, with approximately 1 in 3 achieving reductions of ≥65%. Twelve weeks after stopping treatment, 85% of evaluable patients remained below baseline. Open the document at this passage
Sep 21
Current report 8-K Events of Sep 15
Entered into a material agreement

Recursion Pharmaceuticals amended its Tempus AI agreement to extend the term from five to six years, eliminate convenience termination, and reduce accessible records. It granted Tempus an oncology license to TxFM Model for two years for a non-refundable $12,000,000 fee.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$68.23M
Trailing 12 months
Net income (TTM)
−$475.67M
Trailing 12 months
Revenue growth YoY
+258.5%
Year over year
Operating margin
-725.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-18.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$537.95M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.5%
Year over year · more shares
Price change (1Y)
-32.5%
Trailing year
Short interest
22.8%
Latest settlement · 6.1 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 5, 2026
Q2 FY26

TL;DR. Recursion advanced a previously unexplored neuroscience target with Genentech, reported durable REC-4881 Phase 2 activity ahead of an FDA-path update, obtained IND clearance for REC-7735 with a planned 2H26 trial start, and made progress with Sanofi; partner inflows exceed $500 million. The company lowered 2026 cash operating expense guidance to <$375 million and expects its cash runway to extend into early 2028, although quarterly revenue declined and operating cash use increased.

Bullish
  • + Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing evidence of novel-target discovery and validation.
  • + REC-4881 produced a 43% median polyp-burden reduction after three months with durable off-treatment activity, and an FDA update is expected in 2H26.
  • + REC-7735 received IND clearance and is expected to begin its Phase 1/2 ZINNIA study in 2H26.
  • + REC-1245 continued Phase 1 dose escalation with predictable exposure and target engagement, with additional data expected in 2H26.
Bearish
  • − Second-quarter revenue declined to $7.7 million from $19.2 million because Roche and Genentech revenue was lower following project completions in the prior period.
  • − Quarterly operating cash use increased to $105.9 million from $76.4 million.
  • − Cash, cash equivalents and restricted cash declined to $556.8 million from $753.9 million at year-end 2025.
  • − The safety and efficacy of the investigational medicines have not been established.
  • − Pharmaceutical development carries a high risk of failure before or after regulatory approval.
  • − REC-4881's FDA discussions remain focused on de-risking study design and determining the appropriate primary endpoint for clinical benefit.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.62
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −29%
below
Price vs 50-day avg −34%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −34%
trailing
6-month return −32%
trailing
YTD return −40%
this year
Relative strength −23%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +60 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
22.84% of shares out · ▼ -12.1% MoM · 6.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
357 holders — near 3-yr high, broad support
Squeeze score 62
elevated · 0–100
Fundamentals
Strong
Revenue growth +27%
Y/Y
EPS growth +15%
Y/Y
Free cash flow $-378.3M
Balance sheet $724.6M
net cash
Quant / Vol
risk profile
Very High
Volatility 76%
annualized · 1-yr
Max drawdown −51%
past year
ATR 13.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 2, 2026
2026
Cash operating expense up to $375M
Cash operating expense guidance Non-GAAP up to $375M
OpEx guidance Non-GAAP up to $375M
Cash OpEx vs. 2024 Non-GAAP 40%
2027
Cash operating expense up to $360M
Cash operating expense guidance Non-GAAP up to $360M
OpEx guidance Non-GAAP up to $360M
Previous outlook earlier release · from the 8-K filed Oct 15, 2026

Still-open targets the latest release did not restate under the same label.

Total gross proceeds from October 2026 underwritten offering · October 2026 $200M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−29% Bearish
Price vs 50-day avg
−34% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $3 — 50d above 200d
Institutional flow Accumulating
+1% holders QoQ · +60 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
22.84% of shares out · ▼ -12.1% MoM · 6.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
357 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $2 · 0% Range high $5
vs 200-day avg -29% vs 50-day avg -34%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
annual polyp-burden increase 85% annual —
Cash Operating Expense non-GAAP $271.5M nine months ended September 30, 2026 —
compounds screened to development candidate 204 18 months —
design predictions generated each week 24M each week —
Diagnosed prevalence 55,700 US + EU5 —
disease control rate 91.7% data cutoff: August 21, 2026 —
Estimated prevalence 67,100 US + EU5 —
fewer compounds synthesized vs. industry benchmarks 90% across the portfolio —
Grade 1 or 2 21 data cutoff: August 21, 2026 —
Grade 3 TRAEs 15.4% Data Cutoff Date: 10-Sep-2026 —
maintained reductions below baseline 85% Week 25 —
maintained reductions below baseline 12 weeks off treatment 92% 12 weeks off treatment —
median polyp burden reductions in the lower GI 50% After 12 weeks of treatment —
median polyp burden reductions in the upper GI 55% After 12 weeks of treatment —
median reduction in total polyp burden 47% after 12 weeks of treatment —
oversubscribed follow-on completed $200M October 2026 —
partial responses 3 Data Cutoff Date: 21-Aug-2026 —
patients 26 data cutoff: August 21, 2026 —
patients achieved ≥1-stage Spigelman downstaging 6 Week 13 —
patients had TRAEs ≤ Grade 2 80.8% Data Cutoff Date: 10-Sep-2026 —
patients with a reduction in total polyp burden 87% after 12 weeks of treatment —
patients with equal or greater reductions during the off-treatment period than during treatment 6 Week 25, after 12 weeks off-treatment —
patients with lower GI polyp burden reduction 82% Data Cutoff Date: 10-Sep-2026 —
patients with no TRAEs 1 data cutoff: August 21, 2026 —
patients with polyps >5 mm at baseline with fewer polyps 6 after 12 weeks of treatment —
patients with upper GI polyp burden reduction 92% Data Cutoff Date: 10-Sep-2026 —
patients with ≥65% polyp burden reduction from baseline 4 Week 13 —
polyp burden in the lower GI remained below baseline 70% Week 25 —
POST-COLECTOMY 37,200 US + EU5 —
potential small molecule discovery programs 40 to date —
PRE-COLECTOMY 18,500 US + EU5 —
proprietary data 50 as of 30-Sep-2026 —
reduction in total polyp burden 98% Week 13 —
reductions in total polyp burden 87% Week 13 —
reductions of 65% or more 65% after 12 weeks of treatment —
reductions of ≥98% 98% after 12 weeks of treatment —
remained below baseline 85% Week 25, after 12 weeks off-treatment —
safety-evaluable patients dosed at 4 mg 26 data cutoff in the expanded patient population —
Total Addressable FAP market $15B ’26 —
total partner inflows to date $535M to date —
total upfront and milestone payments achieved from Sanofi under the collaboration $144M the third quarter ended September 30, 2026 —
unconfirmed 1 data cutoff: August 21, 2026 —
Cash as of September 30, 2026 $561M as of September 30, 2026 —
Disease control rate across all doses at 8 weeks 66.7% 8 weeks —
Cash operating expense (six months ended June 30, 2026) non-GAAP $191M six months ended June 30, 2026 —
upfront and milestone payments from the Sanofi collaboration (cumulative) $134M Q2 2026 —
upfront and milestones payments from the Roche and Genentech collaboration (cumulative) $216M Q2 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
RXRX
Recursion Pharmaceuticals, Inc.
this stock
$1.53B -40.1% +26.9% — 22.8%
VRTX
Vertex Pharmaceuticals Inc
$130.58B +13.6% +46.2% 33.2 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.24B +19.3% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$78.90B +561.2% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
357
% held
62.3%
Net QoQ
+26.2M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
189
View
Short & Settlement
Short Interest Falling
Shares short
142.3M
Days to cover
6.1d
Change
-19.7M sh
View
Short Volume
Short vol %
57%
As of
Nov 20, 2026
Short Total
View
Fails to Deliver
FTD shares
36
Value
$153
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
54.7%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$74.7M
Net income (FY)
$-644.8M
EPS diluted
$-1.44
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 2, 2026
This year
20

Recursion reported further positive data from its Phase 1b/2 TUPELO trial of REC-4881 in FAP. After 12 weeks, 87% of patients (13 of 15) had reduced total polyp burden, with a 47% median reduction.

View
Proposed Sales
Value
$155.2K
Shares
40.0K
Filed
Nov 3, 2026
View
Exempt Offerings
Offering
$245.9M
Filed
Nov 12, 2020
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 30, 2026
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Recursion Appoints Fred Hassan as…
Published
Nov 2, 2026
Upcoming events
2
View

Performance

5D 20D 120D MTD YTD
RXRX -23.1% -33.8% -32.1% -39.2% -40.1%
SPY -8.6% -9.2% -9.2% -8.7% +1.2%
vs SPY -14.5% -24.6% -23.0% -30.5% -41.3%
Key facts CIK 1601830 CUSIP 75629V104 13F (30d) 381 filings 327 filers Visit website Investor relations